The oral RAS inhibitor daraxonrasib recently received FDA approval for metastatic pancreatic ductal adenocarcinoma.The drug achieved objective responses in more than 30% of patients with metastatic RAS-mutant non-small cell lung cancer in a phase I/II trial.Daraxonrasib also demonstrated promising antitumor activity in docetaxel-naive patients who had previously received first- or second-line platinum-based chemotherapy and anti-PD-(L)1 therapy.
The landmark oral RAS inhibitor daraxonrasib (Rasonque) showed efficacy in previously treated patients with metastatic RAS-mutant non-small cell lung cancer (NSCLC) in a phase I/II trial.
Among 136 patients treated with daraxonrasib, the percentage who had an objective response was 31% with a dose of 120 mg or less, 34% with doses of 160 to 220 mg, and 37% with a dose of 300 mg, reported Kathryn C. Arbour, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues in the New England Journal of Medicine.
Grade 3 or higher adverse events (AEs) were reported in 54% of patients, with pneumonia (10%), diarrhea (9%), rash (8%), and anemia (5%) occurring in at least 5% of patients. Four grade 5 adverse events occurred.
Mutations in the RAS gene family are among the most common oncogenic drivers of NSCLC, occurring in about 30% of patients, with the majority of tumors harboring RAS mutations for which no targeted therapies are approved.
